Relationship between Osteoprotegrin and estrogen serum level with osteoporosis in postmenopausal Iraqi women

Sura Abdul Kareem  Essmat

doi:10.36371/port.2025.1.3

Authors

Sura Abdul Kareem Essmat College of Pharmacy, Uruk University, Baghdad, Iraq.

Abstract References Downloads Cite Statistics Share Information

Abstract Osteoporosis can define as a major bone disease especially in older women, it correlated with decrease bone density and change in the bone structure that may be increase in bone fragility. Osteoporosis more prevalence in women with age over 50 years old (post menopause), this correlate with estrogen hormone deficiency, this bone loss may be rapid and lead to accelerate bone resorption because of lack of balance occur between osteoclast and osteoblast, increasing in the osteoblast differentiation lead to osteoporosis activation. After menopause estrogen level will decrease due to the lacking occur in eggs produced by ovaries and this will lead to increase synthesis of IL-1, IL-6 and tumor necrosis factor and OPG level will decreased and this will lead to increase bone turnover and osteoporosis, at the same time promote vascular calcification due to increase action of RANKL one bone and vascular cell. Two group included in this study divided into patient group (n=25), age 50 years and over postmenopausal women and control group (n=50), age between 30-50 years' premenopausal women. 5ml of blood was taken from both postmenopausal and premenopausal women. All blood samples for both groups was tested for calcium, alkaline phosphtase and OPG level. OPG level was determined by ELISA technique. Serum level of alkaline phosphatase was found to be higher in postmenopausal group than premenopausal women group (p<0.001). serum calcium level is lower in postmenopausal group than premenopausal women group (p<0.001). serum osteoprotegerin level was higher in postmenopausal group than premenopausal women group (p<0.001). osteoprotegerin (OPG) can be used as indicator of osteoporosis and useful for early diagnosis in postmenopausal women.

Keywords:

osteoprotegrin, osteoporosis, menopaused women, estrogen, calcium

[1] Migliorini F, Giorgino R, Hildebrand F, Spiezia F, Peretti GM, Alessandri-Bonetti M, Eschweiler J, Maffulli N. Fragility fractures: risk factors and management in the elderly. Medicina. 2021;57(10):1119.

[2] Liu S., Li J., Sheng Z., Wu X., Liao E. Relationship between Body Composition and Age, Menopause and Its Effects on Bone Mineral Density at Segmental Regions in Central Southern Chinese Postmenopausal Elderly Women with and without Osteoporosis. Arch. Gerontol. Geriatr. 2011;53:e192–e197. doi: 10.1016/j.archger.2010.09.002.

[3] Prada G, Fita I, Nacu R, Ignat I, Petrescu R, Jugravu O, et al. Risk factors for complications of osteoporosis in older people. Eur Geriatr Med. 2013;4:S25.

[4] Baud'huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, Redini F, Heymann MF, Heymann D (October 2013). "Osteoprotegerin: multiple partners for multiple functions" (PDF). Cytokine & Growth Factor Reviews. 24 (5): 401–9. doi:10.1016/j.cytogfr.2013.06.001

[5] Walsh M.C., Choi Y. Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front. Immunol. 2014;5:511. doi: 10.3389/fimmu.2014.00511.

[6] Rochette L., Meloux A., Rigal E., Zeller M., Cottin Y., Vergely C. The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases. Pharm. Ther. 2018;182:115–132. doi: 10.1016/j.pharmthera.2017.08.015.

[7] Armada L, Marotta Pdos S, Pires FR, Siqueira JF Jr. Expression and distribution of receptor activator of nuclear factor kappa B, receptor activator of nuclear factor kappa B ligand, and osteoprotegerin in periradicular cysts. J Endod. 2015;41:1281–1287.

[8] Kuroda Y., Matsuo K. Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts. World J. Orthop. 2012;3:167–174. doi: 10.5312/wjo.v3.i11.167.

[9] Riggs B.L. The Mechanisms of Estrogen Regulation of Bone Resorption. J. Clin. Investig. 2000;106:1203–1204. doi: 10.1172/JCI11468

[10] Almeida M., Iyer S., Martin-Millan M., Bartell S.M., Han L., Ambrogini E., Onal M., Xiong J., Weinstein R.S., Jilka R.L., et al. Estrogen Receptor-α Signaling in Osteoblast Progenitors Stimulates Cortical Bone Accrual. J. Clin. Investig. 2013;123:394–404. doi: 10.1172/JCI65910.

[11] Eastell R., O’Neill T.W., Hofbauer L.C., Langdahl B., Reid I.R., Gold D.T., Cummings S.R. Postmenopausal Osteoporosis. Nat. Rev. Dis. Primers. 2016;2:16069. doi: 10.1038/nrdp.2016.69.

[12] Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, Bonelli C, Dimai HP, Leb G, Obermayer-Pietsch B. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Wochenschr. 2003;115(9):291–7.

[13] Gurban C.V., Balaş M.O., Vlad M.M., Caraba A.E., Jianu A.M., Bernad E.S., Borza C., Bănicioiu-Covei S., Motoc A.G.M. Bone Turnover Markers in Postmenopausal Osteoporosis and Their Correlation with Bone Mineral Density and Menopause Duration. Rom. J. Morphol. Embryol. 2019;60:1127–1135

[14] Uemura H, Yasui T, Miyatani Y, Yamada M, Hiyoshi M, Arisawa K. Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women. J Endocrinol Invest. 2008;31(2):163–8. et al.

[15] Buchet R, Millan JL, Magne D. Multisystemic functions of alkaline phosphatases. Methods Mol Biol. 2013;1053:27–51. doi:10.1007/978-1-62703-562-0_3

[16] Jiang YX, Tang SY, Wu XP, Yan LF, Liao EY. Biochemical markers of age-related changes in bones turnover and bone mineral density in healthy Chinese men. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008;33(1):53–56.

[17] Fischer V., Haffner-Luntzer M., Amling M., Ignatius A. Calcium and vitamin D in bone fracture healing and post-traumatic bone turnover. Eur. Cell Mater. 2018;35:365–385. doi: 10.22203/eCM.v035a25.

[18] Reid I.R. Osteoporosis: Evidence for vitamin D and calcium in older people. Drug Ther. Bull. 2020;58:122–125. doi: 10.1136/dtb.2019.000063.

[19] Barbu C.G., Arsene A.L., Florea S., Albu A., Sirbu A., Martin S., Nicolae A.C., Burcea-Dragomiroiu G.T.A., Popa D.E., Velescu B.S., et al. Cardiovascular risk assessment in osteoporotic patients using osteoprotegerin as a reliable predictive biochemical marker. Mol. Med. Rep. 2017;16:6059–6067. doi: 10.3892/mmr.2017.7376.

[20] Schoppet M., Henser S., Ruppert V., Stubig T., Al-Fakhri N., Maisch B., Hofbauer L.C. Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent. J. Cell. Biochem. 2007;100:1430–1439. doi: 10.1002/jcb.21129.

PDF

Essmat, S. A. K. . (2025). Relationship between Osteoprotegrin and estrogen serum level with osteoporosis in postmenopausal Iraqi women. Journal Port Science Research, 8(1), 13–17. https://doi.org/10.36371/port.2025.1.3